Axsome Therapeutics (AXSM) awards 16,385 RSUs to its general counsel

Rhea-AI Filing Summary

Murdock Hunter R. reported acquisition or exercise transactions in this Form 4 filing.

Axsome Therapeutics reported that its General Counsel, Hunter R. Murdock, received a grant of 16,385 restricted stock units (RSUs) of company common stock. Each RSU represents a right to receive one share at a future date.

According to the award terms, 25% of the RSUs will vest on the one-year anniversary of the grant date. The remaining units will vest in three substantially equal annual installments, so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered to Murdock upon the earlier of a qualifying change in control, his separation from the company (including termination, death, or total and permanent disability), or seven years from the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Murdock Hunter R.

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	16,385	$0.00	--

Holdings After Transaction: Restricted Stock Units — 16,385 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murdock Hunter R.

(Last) (First) (Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/26/2026		A		16,385		(2)	02/26/2036	Common Stock	16,385	$0	16,385	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant.

	/s/ Hunter Murdock	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Axsome Therapeutics (AXSM) report for Hunter R. Murdock?

Axsome Therapeutics reported that General Counsel Hunter R. Murdock received a grant of 16,385 restricted stock units. These RSUs give him the right to receive an equal number of Axsome common shares if the vesting and settlement conditions are met.

How many restricted stock units were granted in the latest Axsome (AXSM) Form 4?

The filing shows a grant of 16,385 restricted stock units to Axsome’s General Counsel. Each restricted stock unit represents a contingent right to receive one share of Axsome Therapeutics common stock, subject to the vesting schedule and settlement conditions described in the award.

What is the vesting schedule for the 16,385 RSUs granted by Axsome (AXSM)?

Twenty-five percent of the RSUs vest on the one-year anniversary of the grant date. The remaining units vest in three substantially equal annual installments, so that all 16,385 RSUs are fully vested by February 26, 2030, if the service conditions are satisfied.

When will the Axsome (AXSM) RSU shares be delivered to Hunter R. Murdock?

Vested RSU shares will be delivered upon the earlier of a qualifying change in control, Murdock’s separation from Axsome, or seven years from the grant. Separation includes termination with or without cause, death, or total and permanent disability under the company’s 2025 Long-Term Incentive Plan.

What does each restricted stock unit represent in the Axsome (AXSM) grant?

Each restricted stock unit represents a contingent right to receive one share of Axsome common stock. The units do not deliver shares immediately; instead, shares are issued later if the vesting schedule and specified delivery triggers are satisfied under the plan terms.

What role does Hunter R. Murdock hold at Axsome Therapeutics (AXSM)?

Hunter R. Murdock is identified as an officer of Axsome Therapeutics serving as General Counsel. The Form 4 reports his acquisition of 16,385 restricted stock units as a grant or award under the company’s 2025 Long-Term Incentive Plan, subject to vesting and delivery conditions.